J90 Stock Chart & Stats
€0.33
>-€0.01(-2.36%)
At close: 4:00 PM EDT
€0.33
>-€0.01(-2.36%)
Day’s Range― - ―
52-Week Range€0.24 - €0.54
Previous CloseN/A
Volume0.00
Average Volume (3M)1.45K
Market Cap
€29.33M
Enterprise Value€49.36M
Total Cash (Recent Filing)€1.01M
Total Debt (Recent Filing)€52.00K
Price to Earnings (P/E)―
Beta-0.22
Next Earnings
Nov 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding77,746,750
10 Day Avg. Volume271
30 Day Avg. Volume1,446
Financial Highlights & Ratios
PEG Ratio-1.72
Price to Book (P/B)13.94
Price to Sales (P/S)0.00
P/FCF Ratio-8.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low leverage limits fixed financial obligations and reduces exposure to interest or refinancing pressure. For an early-stage biotech, this preserves flexibility to direct available capital toward research and development rather than servicing substantial debt.
Exosome CNS PlatformA focused exosome platform gives NurExone a potentially reusable development foundation across multiple central nervous system indications. The acute spinal cord injury program and earlier CNS concepts create opportunities to build value beyond a single candidate.
Losses Not Accelerating DramaticallyAlthough profitability remains distant, relatively stable losses provide some evidence that operating deterioration is not rapidly worsening. If management maintains spending discipline while advancing the pipeline, this stability could support more predictable capital planning over the next several quarters.
Bears Say
No Product RevenueWith no product revenue, NurExone has not yet demonstrated commercial demand or an operating revenue engine. Future value therefore depends heavily on successful clinical and regulatory progress before the pipeline can support recurring sales or licensing economics.
Persistent Operating LossesContinuing sizable losses show that current operations do not fund themselves and that the business remains dependent on development financing. Persistent deficits can constrain strategic flexibility and increase the importance of achieving meaningful pipeline milestones.
Cash Burn And Shrinking EquitySustained negative operating and free cash flow consume resources while declining equity indicates pressure from losses and dilution or burn. If this pattern continues, the company may need additional external capital to keep funding research and development.
NurExone Biologic News
J90 FAQ
What was NurExone Biologic’s price range in the past 12 months?
NurExone Biologic lowest stock price was €0.24 and its highest was €0.54 in the past 12 months.
What is NurExone Biologic’s market cap?
NurExone Biologic’s market cap is €29.33M.
When is NurExone Biologic’s upcoming earnings report date?
NurExone Biologic’s upcoming earnings report date is Nov 20, 2026 which is in 33 days.
How were NurExone Biologic’s earnings last quarter?
NurExone Biologic released its earnings results on Aug 31, 2026. The company reported €0.018 earnings per share for the quarter, beating the consensus estimate of -€0.018 by €0.036.
Is NurExone Biologic overvalued?
According to Wall Street analysts NurExone Biologic’s price is currently Overvalued.
Does NurExone Biologic pay dividends?
NurExone Biologic does not currently pay dividends.
What is NurExone Biologic’s EPS estimate?
NurExone Biologic’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NurExone Biologic have?
NurExone Biologic has 77,746,750 shares outstanding.
What happened to NurExone Biologic’s price movement after its last earnings report?
NurExone Biologic reported an EPS of €0.018 in its last earnings report, beating expectations of -€0.018. Following the earnings report the stock price went up 0.909%.
Which hedge fund is a major shareholder of NurExone Biologic?
Currently, no hedge funds are holding shares in DE:J90
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NurExone Biologic
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury. The company was founded on June 27, 2011 and is headquartered in Toronto, Canada.
Technical Analysis
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
Hemostemix
―
Sernova
―
Vaxil Bio
―